Demographic and disease specific characteristics
| Psoriasis patients | Healthy controls | |
|---|---|---|
| Demographic characteristics | ||
| N of subjects | 55 | 47 |
| Sex (male/female) | 35/20 | 24/23 |
| Age (years) | 49.0±11.4 | 45.7±12.9 |
| Height (cm) | 174.2±9.3 | 174.0±10.4 |
| Weight (kg) | 84.9±20.1 | 78.0±18.4 |
| BMI | 27.9±5.6 | 25.0±4.7 |
| Smokers N (%) | 16 (29.1) | 11 (23.4) |
| Disease specific characteristics | ||
| Duration of skin psoriasis (years) | 15.2±15.4 | – |
| PASI | 6.2±8.0 | – |
| DLQI | 6.3±6.1 | – |
| Phenotypic characteristics | ||
| Psoriasis vulgaris N (%) | 40 (72.7) | – |
| Other subtypes N (%) | 15 (27.3) | – |
| Nail involvement N (%) | 28 (50.9) | – |
| Scalp involvement N (%) | 16 (29.1) | – |
| Other clinical characteristics | ||
| ACPA positive N (%) | 0 | – |
| RF positive N (%)* | 4 (7.3) | – |
| C reactive protein (mg/L)† | 3.8±4.6 | – |
| Treatment modalities | ||
| No current treatment N (%) | 15 (27.3) | – |
| Topical therapies N (%) | 25 (45.5) | – |
| Fumaric acid N (%) | 11 (20.0) | – |
| Systemic agents N (%) | 9 (16.4) | – |
| TNF-i N (%) | 3 (5.5) | – |
| Ustekinumab N (%) | 1 (1.8) | – |
*All four patients had low-titre RF (<50 IE/mL).
†Normal value <5 mg/mL.
ACPA, anticyclic citrullinated peptide antibodies; BMI, body mass index; DLQI, Dermatology Life Quality Index; RF, rheumatoid factor.